title: Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.
abstract: The highly immunogenic human tumor antigen NY-ESO-1 (ESO) is a target of choice for anti-cancer immune therapy. In this study, we assessed spontaneous antibody (Ab) responses to ESO in a large cohort of patients with primary breast cancer (BC) and addressed the correlation between the presence of anti-ESO Ab, the expression of ESO in the tumors and their characteristics. We found detectable Ab responses to ESO in 1% of the patients. Tumors from patients with circulating Ab to ESO exhibited common characteristics, being mainly hormone receptor (HR)⁻ invasive ductal carcinomas of high grade, including both HER2⁻ and HER2⁺ tumors. In line with these results, we detected ESO expression in 20% of primary HR⁻ BC, including both ESO Ab⁺ and Ab⁻ patients, but not in HR⁺ BC. Interestingly, whereas expression levels in ESO⁺ BC were not significantly different between ESO Ab⁺ and Ab⁻ patients, the former had, in average, significantly higher numbers of tumor-infiltrated lymph nodes, indicating that lymph node invasion may be required for the development of spontaneous anti-tumor immune responses. Thus, the presence of ESO Ab identifies a tumor subtype of HR⁻ (HER2⁻ or HER2⁺) primary BC with frequent ESO expression and, together with the assessment of antigen expression in the tumor, may be instrumental for the selection of patients for whom ESO-based immunotherapy may complement standard therapy.
authors: Institut National de la Santé et de la Recherche Médicale, Unité 892, CLCC René Gauducheau, Saint Herblain, France.
authors: Ahmed
authors: A
authors: Hamaï
authors: Karine
authors: K
authors: Duperrier-Amouriaux
authors: Pascale
authors: P
authors: Pignon
authors: Isabelle
authors: I
authors: Raimbaud
authors: Lorenzo
authors: L
authors: Memeo
authors: Cristina
authors: C
authors: Colarossi
authors: Vincenzo
authors: V
authors: Canzonieri
authors: Tiziana
authors: T
authors: Perin
authors: Jean-Marc
authors: JM
authors: Classe
authors: Mario
authors: M
authors: Campone
authors: Pascal
authors: P
authors: Jézéquel
authors: Loïc
authors: L
authors: Campion
authors: Maha
authors: M
authors: Ayyoub
authors: Danila
authors: D
authors: Valmori
mesh_terms: D000912:Antibodies, Neoplasm / Q000276:immunology*; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D001943:Breast Neoplasms / Q000235:genetics / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D045744:Cell Line, Tumor; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008565:Membrane Proteins / Q000235:genetics / Q000276:immunology*; D018579:Patient Selection; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000172:deficiency / Q000378:metabolism; D011980:Receptors, Progesterone / Q000172:deficiency / Q000378:metabolism
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D008565:Membrane Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C104948:CTAG1B protein, human